Germany’s Boehringer Ingelheim, in collaboration with Scotland’s national economic development agency Scottish Enterprise, has co-led a GBP 4.3 million (USD 5.3 million) seed funding round for Scotland-based biotechnology company Glox Therapeutics. The investment will enable Glox to establish new laboratories and expand its team, bolstering its mission to develop precision antibiotics against antibiotic-resistant Gram-negative bacteria.
Glox Therapeutics’ Mission and Development Pipeline
Established in February of this year, Glox Therapeutics is dedicated to combating the growing threat of antibiotic resistance. The company’s development pipeline is centered on engineered bacteriocins, proteic toxins that bacteria naturally produce to combat rival strains of the same or related species. These bacteriocins offer a promising approach to precision antibiotics, as their selectivity towards pathogens is anticipated to help preserve the microbiomes of patients, avoiding the broad disruption associated with traditional antibiotics.
Expanding Capabilities and Team
With the newly secured funds, Glox Therapeutics will enhance its research and development capabilities by setting up state-of-the-art laboratories and expanding its team of scientific experts. This expansion is crucial for accelerating the company’s efforts in the discovery and development of novel antibiotics that can effectively target antibiotic-resistant bacteria without harming beneficial microbial populations.- Flcube.com
